Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC) and can have a significant impact on patient morbidity and quality of life. We assessed the effect of adalimumab (ADA) therapy on the resolution of EIMs among patients with moderate to severe UC in clinical pra...

Full description

Bibliographic Details
Main Authors:	Travis, S, Feagan, B, Peyrin-Biroulet, L, Panaccione, R, Danese, S, Lazar, A, Robinson, A, Thakkar, R, Pappalardo, B, Petersson, J, Bereswill, M, Chen, N, Skup, M
Format:	Journal article
Published:	Oxford University Press 2017

Similar Items

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
by: Travis, S, et al.
Published: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results From InspirADA.
by: Travis, S, et al.
Published: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
by: Travis, S, et al.
Published: (2017)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
by: Sandborn, W, et al.
Published: (2016)

Early Intervention in Ulcerative Colitis: Ready for Prime Time?
by: Virginia Solitano, et al.
Published: (2020-08-01)

Does it all ADA up? Adalimumab for ulcerative colitis.
by: Travis, S
Published: (2011)

Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
by: Walsh, A, et al.
Published: (2018)

Immune Thrombocytopenic Purpura as an Extraintestinal Manifestation in a Patient with Ulcerative Colitis
by: Renata de Medeiros Dutra, et al.
Published: (2022-03-01)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
by: David T. Rubin, et al.
Published: (2021-05-01)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
by: Virginia Solitano, et al.
Published: (2020-09-01)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
by: Napolitano M, et al.
Published: (2022-06-01)

Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
by: Yiyoung Kwon, et al.
Published: (2022-05-01)

Meta‐analysis of the association of extraintestinal manifestations with the development of pouchitis in patients with ulcerative colitis
by: K. Hata, et al.
Published: (2019-08-01)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
by: Ferdinando D’Amico, et al.
Published: (2019-05-01)

Multiple extraintestinal manifestations in a patient with acute severe ulcerative colitis: a case report
by: Eun Young Park, et al.
Published: (2022-12-01)

Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country
by: Jesús K. Yamamoto-Furusho, et al.
Published: (2020-10-01)

Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis?
by: Myriam Renaud, et al.
Published: (2022-07-01)

Albumin change predicts failure in ulcerative colitis treated with adalimumab
by: Natsuki Ishida, et al.
Published: (2024-01-01)

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
by: Laurel L. Wessman, BS, et al.
Published: (2017-07-01)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
by: Freeman HJ
Published: (2013-11-01)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
by: Assasi Nazila, et al.
Published: (2009-12-01)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
by: Armuzzi A, et al.
Published: (2013-04-01)

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
by: Zhdanava M, et al.
Published: (2024-04-01)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
by: Vuitton, L, et al.
Published: (2017)

Leaving behind the Mucosa: Advances and Future Directions of Intestinal Ultrasound in Ulcerative Colitis
by: Alberto Barchi, et al.
Published: (2023-12-01)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
by: Sebastian Hoffmann, et al.
Published: (2018-05-01)

ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY
by: Patrícia ZACHARIAS, et al.
Published: (2017-10-01)

Leukocytoclastic Vasculitis as a Rare Dermatologic Extraintestinal Manifestation of Ulcerative Colitis in an Elderly Patient with Positive PR3-ANCA
by: Jacky Ng, et al.
Published: (2021-01-01)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
by: Shinji Okabayashi, et al.
Published: (2017-10-01)

Exploring genetic associations of Crohn’s disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations
by: Chengdong Yu, et al.
Published: (2024-02-01)

Ulcerative Colitis: Shifting Sands
by: Geert R. A. M. D’Haens, et al.
Published: (2019-03-01)

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis
by: Sarah Bencardino, et al.
Published: (2023-07-01)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
by: Travis, S, et al.
Published: (2012)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
by: Martin Wasserbauer, et al.
Published: (2022-01-01)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
by: Vandana Midha, et al.
Published: (2018-01-01)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
by: Bénédicte Caron, et al.
Published: (2023-01-01)

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease Eficacia del adalimumab en el tratamiento de las manifestaciones extraintestinales de la enfermedad de Crohn
by: Manuel Barreiro-de-Acosta, et al.
Published: (2012-09-01)

Clinical outcomes and risk factors of secondary extraintestinal manifestation in ulcerative colitis: results of a multicenter and long-term follow-up retrospective study
by: Weimin Xu, et al.
Published: (2019-06-01)

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis
by: Keijiro Numa, et al.
Published: (2023-10-01)

Review article: defining remission in ulcerative colitis.
by: Travis, S, et al.
Published: (2011)